# Graftech International Ltd: Form 10-Q for the period ended Sep 30, 2018

- Company: [Graftech International Ltd](/companies/eaf.md) (CIK 931148)
- Form: 10-Q
- Filed: 2018-11-02
- Accepted by EDGAR: Nov 2, 2018, 13:57 ET
- Period: 2018-09-30
- Accession: 0000931148-18-000034
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/931148/000093114818000034/a2018-q3.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/931148/000093114818000034/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2018-09-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2018-07-01 to 2018-09-30 | $454.9m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 9 months, 2018-01-01 to 2018-09-30 | $1.36bn | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months, 2018-07-01 to 2018-09-30 | $180.3m | us-gaap:CostOfGoodsAndServicesSold |
| Cost of revenue | 9 months, 2018-01-01 to 2018-09-30 | $491.3m | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 3 months, 2018-07-01 to 2018-09-30 | $274.6m | us-gaap:GrossProfit |
| Gross profit | 9 months, 2018-01-01 to 2018-09-30 | $871.8m | us-gaap:GrossProfit |
| Research and development | 3 months, 2018-07-01 to 2018-09-30 | $518.0k | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 9 months, 2018-01-01 to 2018-09-30 | $1.5m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months, 2018-07-01 to 2018-09-30 | $14.2m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 9 months, 2018-01-01 to 2018-09-30 | $46.3m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months, 2018-07-01 to 2018-09-30 | $259.9m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months, 2018-01-01 to 2018-09-30 | $823.9m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months, 2018-07-01 to 2018-09-30 | $33.9m | us-gaap:InterestExpense |
| Interest expense | 9 months, 2018-01-01 to 2018-09-30 | $100.4m | us-gaap:InterestExpense |
| Income tax | 3 months, 2018-07-01 to 2018-09-30 | $24.9m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months, 2018-01-01 to 2018-09-30 | $36.3m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2018-07-01 to 2018-09-30 | $199.5m | us-gaap:NetIncomeLoss |
| Net income | 9 months, 2018-01-01 to 2018-09-30 | $624.6m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2018-07-01 to 2018-09-30 | $0.67 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months, 2018-01-01 to 2018-09-30 | $2.08 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2018-07-01 to 2018-09-30 | $0.67 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months, 2018-01-01 to 2018-09-30 | $2.08 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2018-07-01 to 2018-09-30 | 296,145,453 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months, 2018-01-01 to 2018-09-30 | 300,178,704 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months, 2018-01-01 to 2018-09-30 | $612.2m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months, 2018-01-01 to 2018-09-30 | $47.6m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Dividends paid | 9 months, 2018-01-01 to 2018-09-30 | $1.32bn | us-gaap:PaymentsOfDividends |
| Share repurchases | 9 months, 2018-01-01 to 2018-09-30 | $225.0m | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | at 2018-09-30 | $102.5m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2018-09-30 | $630.6m | us-gaap:AssetsCurrent |
| Total assets | at 2018-09-30 | $1.50bn | us-gaap:Assets |
| Current liabilities | at 2018-09-30 | $282.7m | us-gaap:LiabilitiesCurrent |
| Long-term debt | at 2018-09-30 | $2.08bn | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | at 2018-09-30 | $106.3m | us-gaap:LongTermDebtCurrent |
| Short-term borrowings | at 2018-09-30 | $106.3m | us-gaap:ShortTermBorrowings |
| Shareholders' equity | at 2018-09-30 | −$1.04bn | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 63,826 characters.

### Overview

We are a leading manufacturer of high quality graphite electrode products essential to the production of electric arc furnace ("EAF") steel and other ferrous and non‑ferrous metals. We believe that we have the most competitive portfolio of low‑cost graphite electrode manufacturing facilities in the industry, including three of the five highest capacity facilities in the world (excluding China). We are the only large scale graphite electrode producer that is substantially vertically integrated into petroleum needle coke, the primary raw material for graphite electrode manufacturing, which is currently in limited supply. Between 1984 and 2011, EAF steelmaking was the fastest‑growing segment of the steel sector, with production increasing at an average rate of 3.5% per year, based on World Steel Association ("WSA") data. Historically, EAF steel production has grown faster than the overall steel market due to the greater resilience, more variable cost structure, lower capital intensity and more environmentally friendly nature of EAF steelmaking. This trend was partially reversed between 2011 and 2015 due to global steel production overcapacity driven largely by Chinese blast furnace ("BOF") steel production. Beginning in 2016, efforts by the Chinese government to restructure China’s domestic steel industry have led to limits on BOF steel production and lower export levels, and developed economies, which typically have much larger EAF steel industries, have instituted a number of trade policies in support of domestic steel producers. As a result, since 2016, the EAF steel market has rebounded strongly and resumed its long‑term growth trajectory. This revival in EAF steel production has resulted in increased demand for our graphite electrodes.

At the same time, two supply‑side structural changes have contributed to recent record high prices of graphite electrodes. First, ongoing consolidation and rationalization of graphite electrode production capacity have limited the ability of graphite electrode producers to meet demand. We estimate that approximately 20% of graphite electrode industry production capacity (excluding China) has been closed or repurposed since the beginning of 2014, and we believe the majority of these closures represent permanent reductions. Second, demand for petroleum needle coke has outpaced supply due to increasing demand for petroleum needle coke for lithium‑ion batteries used in electric vehicles. As a result, graphite electrode prices have recently reached record high prices. We have implemented a commercial strategy to sell 60% to 65% of our production capacity through three‑ to five‑year take‑or‑pay contracts. These contracts define volumes and prices, along with price‑escalation mechanisms for inflation, and include significant termination payments (typically, 50% to 70% of remaining contracted revenue) and, in certain cases, parent guarantees and collateral arrangements to manage our customer credit risk. We expect a high degree of stability in our future operating results due to these contracts. We have entered into three‑to‑five‑year take‑or‑pay contracts to sell approximately 132,406, 138,446, 134,831, 117,600 and 112,883 metric tons ("MT") in 2018, 2019, 2020, 2021 and 2022, respectively. We may enter into additional take-or-pay contracts in the future.

### GrafTech's Transformation

Since 2012, we have executed a three‑part transformation plan to improve our competitive position and allow us to better serve our customers. Since 2012, we have achieved annual fixed manufacturing cost improvements of $80 million, annual capital expenditure requirement reductions of $45 million and annual overhead expense reductions of approximately $65 million, all while also improving the productivity of our plant network. We have strategically shifted production from our lowest to our highest production capacity facilities to increase fixed cost absorption. This, coupled with a recovery in customer demand, resulted in a steady increase in our capacity utilization, reaching 100% in the third quarter of 2018 (excluding our temporarily idled St. Marys, Pennsylvania facility). We have also reduced our annual overhead expenses by approximately $65 million since 2012 by simplifying our corporate structure from a conglomerate model to a centralized business focused exclusively on the production of graphite electrodes and petroleum needle coke, and we have streamlined and combined our workforce and various administrative functions for efficiency, and eliminated research and development ("R&D") functions unrelated to graphite electrodes. In 2018, we expect to have maintenance capital expenditures of approximately $35 million. In addition to our fixed cost reductions, we have been able to achieve significant productivity improvements and variable cost reductions across our plants since 2014. We are currently implementing an operational improvement and debottlenecking initiative, which we expect will increase our current operating production capacity by the end of 2018, allowing us to achieve further improvements in our cost structure. As a result of our prior operational improvement activities, we are able to achieve this large capacity increase with specific, highly targeted capital investments. This debottlenecking initiative is expected to result in approximately $42 million of capital expenditures, slightly higher than previous estimates due mainly to currency impacts. The majority of costs associated with this initiative will be expended in 2018. We expect our debottlenecking initiative along with our maintenance capital expenditures to result in approximately $70 million of total capital expenditures in 2018.

In light of improved market conditions, the long lead time required to produce our products, our position as one of the market’s largest producers and our ability, through our substantial vertical integration with Seadrift Coke L.P. ("Seadrift"), to provide customers with a reliable long‑term supply of graphite electrodes despite the market shortage of petroleum needle coke, we have implemented a commercial strategy to sell graphite electrodes through three-to-five-year take-or-pay contracts. Additionally, the divestiture of our non-core legacy Engineered Solutions businesses in 2016 and 2017 has allowed our management team to focus on our core competency of graphite electrode production and generated approximately $60 million in cash proceeds and release of working capital. By focusing our management’s attention and R&D spending exclusively on the graphite electrode business, we have been able to meaningfully improve the quality of our graphite electrodes, repositioning ourselves as an industry quality leader and improving our relationships with strategic customers.

### Global economic conditions and outlook

The graphite electrode industry has historically followed the growth of the EAF steel industry and, to a lesser extent, the steel industry as a whole, which has been highly cyclical and affected significantly by general economic conditions. Historically, EAF steel production has grown faster than the overall steel market due to the greater resilience, more variable cost structure, lower capital intensity and more environmentally friendly nature of EAF steelmaking.

This growth trend has resumed after a decline in EAF steelmaking between 2011 and 2015, as Chinese steel production, which is predominantly BOF‑based, grew significantly, taking market share from EAF steel producers. Throughout 2015 and 2016, our business faced significant headwinds in the major industries that we served, including slow economic growth and stagnation in steel production year‑over‑year. These factors exerted continued downward pressure on prices for our products, which negatively impacted our recent historical profitability. Additionally, in 2015, steel producers utilized BOFs over EAFs at rates higher than we had historically seen, pressuring the prices of and demand for graphite electrodes, as steel consumers in the United States and Europe, our largest markets, increased imports of low‑cost steel products, primarily from China. Additionally, prices for iron ore, the key raw material for BOFs, declined faster than scrap steel, the key raw material in EAF production. While a decline in the price of oil benefited our cost structure overall, it contributed to lower prices for petroleum needle coke and, indirectly, graphite electrodes.

Graphite electrodes saw further pricing pressure in the first half of 2016, but EAF production started to recover during the second half of 2016, which indicated a potential bottoming out in prices. Costs of the key raw materials used to run BOFs increased, and the price of scrap steel decreased, re‑balancing the economics of EAF mills relative to BOFs. These developments resulted in an increase in our sales volume over the prior year; however, the decline in prices more than offset the volume increase. Because customers historically negotiated annual agreements in the third and fourth quarters of each calendar year for graphite electrodes to be delivered the following year, increases in price often lagged behind increases in volume. Nonetheless, a decline in the price of oil and our rationalization initiatives significantly improved our cost structure and positioned us to benefit from a potential recovery.

The outlook for general economic and industry‑specific growth brightened in 2017. In its January 2018 report, the International Monetary Fund ("IMF") increased its estimated global growth rate for 2018 and 2019 to 3.9%, which was 0.2% higher than 2017. However, in its October 2018 World Economic Outlook publication, the IMF revised its 2018 and 2019 growth estimates back to 2.7% as a result of the risk surrounding recently announced trade measures and slower than expected growth in the euro area. The WSA's October 2018 Short Range Outlook estimated global steel production outside of China would increase by 2.1% in 2018 and 2.7% in 2019.

Other macroeconomic and industry trends have created significant increases in demand for graphite electrodes. Beginning in 2016, efforts by the Chinese government to eliminate excess steelmaking production capacity and improve environmental and health conditions have led to limits on Chinese BOF steel production, including the closure of over 200 million MT of its steel production capacity, based on data from S&P Global Platts and the Ministry of Commerce of the People’s Republic of China. In 2017, Chinese steel exports fell by more than 30% from 2016. Chinese steel exports continued to decline in 2018 and are down approximately 6.5% through September 2018 according to the National Bureau of Statistics of China. Reflecting the reduction in steel production capacity, as a result, the historical growth trend of EAF steelmaking relative to the overall steel market resumed and has led to increased demand for our graphite electrodes. At the same time, ongoing consolidation and rationalization of graphite electrode production capacity has limited the ability of graphite electrode producers to meet this demand. Prior to this improvement in demand, the electrode industry experienced an extended, five‑year downturn, resulting in a reduction of production capacity outside of China of approximately 200,000 MT (or approximately 20%) since the beginning of 2014.

Petroleum needle coke, which is the primary raw material for graphite electrode manufacturing, and coal tar pitch, which is a raw material used in our manufacturing processes, are currently in limited supply. Demand for petroleum needle coke has outpaced supply due to increasing demand for petroleum needle coke in the production of lithium‑ion batteries used in electric vehicles. Increased demand has led to pricing increases for petroleum needle coke in the current market. While we believe that our substantial vertical integration into petroleum needle coke through our ownership of Seadrift provides a significant cost advantage relative to our competitors in periods of tight petroleum needle coke supply, such as the current market environment, we currently purchase approximately 25% of our petroleum needle coke requirements from external sources. Going forward, we expect to purchase approximately one third of our needle coke requirements from external sources, given the expected increase in our graphite electrode capacity from our debottlenecking initiative. As a result, we expect to incur increased raw material costs. Additionally, supply of coal tar pitch, a byproduct of coking metallurgical coal used in BOF steelmaking, has fallen as a result of the reduced demand for metallurgical coke for BOF steel furnaces. Consequently, prices for coal tar pitch increased starting in the second half of 2017.

These factors have led to supply constraints for our products. There are indications that this demand and supply imbalance could persist for some time. As a result, graphite electrode prices have recently reached record high prices.

We expect the results of our operational improvement and debottlenecking initiative to be completed by the end of the fourth quarter of 2018. This incremental volume from our capacity expansion will be available for sale to customers going forward. As a result of our recent three-to-five-year contracting initiative and other sales commitments, substantially all of our 2018 production capacity is now contracted or committed by purchase orders. We are on target to increase annual production capacity by 21% to 202,000 MT by year end. St. Marys is graphitizing and machining some semi-finished electrodes sourced from Monterrey in order to leverage existing infrastructure.

We continue to experience higher input costs which will affect our cost of goods sold in future quarters. Additionally, during the fourth quarter, our planned maintenance outage at our Seadrift needle coke facility will decrease production levels at that facility. We expect to produce approximately 110,000 MT of needle coke in 2018. We expect to produce approximately 125,000 MT of needle coke in 2019, as we do not have a planned maintenance outage in 2019 and we expect a modest productivity enhancement related to our efficiency improvement project.

### Key metrics used by management to measure performance

In addition to measures of financial performance presented in our Condensed Consolidated Financial Statements in accordance with GAAP, we use certain other financial measures and operating metrics to analyze the performance of our company. The “non‑GAAP” financial measures consist of EBITDA from continuing operations and adjusted EBITDA from continuing operations, which help us evaluate growth trends, establish budgets, assess operational efficiencies and evaluate our overall financial performance. The key operating metrics consist of sales volume, weighted average realized price, production volume, production capacity and capacity utilization.

### Key financial measures

*(in thousands)*

|  | For the three months ended September 30, 2018 | 2017 | For the nine months ended September 30, 2018 | 2017 |
| --- | ---: | ---: | ---: | ---: |
| Net sales | $454,890 | $137,245 | $1,363,121 | $358,298 |
| Net income (loss) | 199,466 | (3,919) | 624,587 | (47,646) |
| EBITDA from continuing operations(1) | 274,406 | 20,125 | 807,317 | 31,969 |
| Adjusted EBITDA from continuing operations(1) | 276,812 | 22,202 | 879,108 | 38,655 |

31

### Key operating metrics

*(in thousands, except price data)*

|  | For the three months ended September 30, 2018 | 2017 | For the nine months ended September 30, 2018 | 2017 |
| --- | ---: | ---: | ---: | ---: |
| Sales volume (MT)(2) | 45 | 44 | 133 | 129 |
| Weighted average realized price(3) | $9,744 | $2,903 | $9,932 | $2,547 |
| Production volume (MT)(4) | 39 | 38 | 127 | 122 |
| Production capacity excluding St. Marys during idle period (MT)(5)(6) | 39 | 38 | 128 | 123 |
| Capacity utilization excluding St. Marys during idle period(5)(7) | 100% | 100% | 99% | 99% |
| Total production capacity (MT)(6) | 46 | 45 | 149 | 144 |
| Total capacity utilization(7) | 85% | 84% | 85% | 85% |

(1) See below for more information and a reconciliation of EBITDA and adjusted EBITDA to net income (loss), the most directly comparable financial measure calculated and presented in accordance with GAAP.

(2) Sales volume reflects the total volume of graphite electrodes sold for which revenue has been recognized during the period. See below for more information on our key operating metrics.

(3) Weighted average realized price reflects the total revenues from sales of graphite electrodes for the period divided by the graphite electrode sales volume for that period. See below for more information on our key operating metrics.

(4) Production volume reflects graphite electrodes produced during the period. See below for more information on our key operating metrics.

(5) The St. Marys, Pennsylvania facility was temporarily idled effective the second quarter of 2016 except for the machining of semi‑finished products sourced from other plants. In the first quarter of 2018, our St. Marys facility began graphitizing a limited amount of electrodes sourced from our Monterrey, Mexico facility.

(6) Production capacity reflects expected maximum production volume during the period under normal operating conditions, standard product mix and expected maintenance downtime. Actual production may vary. See below for more information on our key operating metrics.

(7) Capacity utilization reflects production volume as a percentage of production capacity. See below for more information on our key operating metrics.

### Non‑GAAP financial measures

EBITDA from continuing operations and adjusted EBITDA from continuing operations are non‑GAAP financial measures. We define EBITDA from continuing operations, a non‑GAAP financial measure, as net income or loss plus interest expense, minus interest income, plus income taxes, discontinued operations and depreciation and amortization from continuing operations. We define adjusted EBITDA from continuing operations as EBITDA from continuing operations plus any pension and Other post-employment benefit ("OPEB") plan expenses, impairments, rationalization‑related charges, costs related to our initial public offering, non‑cash gains or losses from foreign currency remeasurement of non‑operating liabilities in our foreign subsidiaries where the functional currency is the U.S. dollar, related party Tax Receivable Agreement expense, stock-based compensation and non‑cash fixed asset write‑offs. Adjusted EBITDA from continuing operations is the primary metric used by our management and our Board of Directors to establish budgets and operational goals for managing our business and evaluating our performance.

We monitor adjusted EBITDA from continuing operations as a supplement to our GAAP measures, and believe it is useful to present to investors, because we believe that it facilitates evaluation of our period‑to‑period operating performance by eliminating items that are not operational in nature, allowing comparison of our recurring core business operating results over multiple periods unaffected by differences in capital structure, capital investment cycles and fixed asset base. In addition, we believe adjusted EBITDA from continuing operations and similar measures are widely used by investors, securities analysts, ratings agencies, and other parties in evaluating companies in our industry as a measure of financial performance and debt‑service capabilities.

Our use of adjusted EBITDA from continuing operations has limitations as an analytical tool, and you should not consider it in isolation or as a substitute for analysis of our results as reported under GAAP. Some of these limitations are:

- adjusted EBITDA from continuing operations does not reflect changes in, or cash requirements for, our working capital needs;
- adjusted EBITDA from continuing operations does not reflect our cash expenditures for capital equipment or other contractual commitments, including any capital expenditure requirements to augment or replace our capital assets;
- adjusted EBITDA from continuing operations does not reflect the interest expense or the cash requirements necessary to service interest or principal payments on our indebtedness;
- adjusted EBITDA from continuing operations does not reflect tax payments that may represent a reduction in cash available to us;
- adjusted EBITDA from continuing operations does not reflect expenses relating to our pension and OPEB plans;
- adjusted EBITDA from continuing operations does not reflect impairment of long‑lived assets and goodwill;
- adjusted EBITDA from continuing operations does not reflect the non‑cash gains or losses from foreign currency remeasurement of non‑operating liabilities in our foreign subsidiaries where the functional currency is the U.S. dollar;
- adjusted EBITDA from continuing operations does not reflect IPO expenses;
- adjusted EBITDA from continuing operations does not reflect related party Tax Receivable Agreement expense;
- adjusted EBITDA from continuing operations does not reflect rationalization‑related charges, stock-based compensation or the non‑cash write‑off of fixed assets; and
- other companies, including companies in our industry, may calculate EBITDA from continuing operations and adjusted EBITDA from continuing operations differently, which reduces its usefulness as a comparative measure.

In evaluating EBITDA from continuing operations and adjusted EBITDA from continuing operations, you should be aware that in the future, we will incur expenses similar to the adjustments in this presentation. Our presentations of EBITDA from continuing operations and adjusted EBITDA from continuing operations should not be construed as suggesting that our future results will be unaffected by these expenses or any unusual or non‑recurring items. When evaluating our performance, you should consider EBITDA from continuing operations and adjusted EBITDA from continuing operations alongside other financial performance measures, including our net income (loss) and other GAAP measures.

The following table reconciles our non‑GAAP key financial measures to the most directly comparable GAAP measures:

*(in thousands)*

|  | For the three months ended September 30, 2018 | 2017 | For the nine months ended September 30, 2018 | 2017 |
| --- | ---: | ---: | ---: | ---: |
| **Net income (loss)** | 199,466 | (3,919) | 624,587 | (47,646) |
| Add: |  |  |  |  |
| Discontinued operations | 726 | (3,234) | (585) | 4,882 |
| Depreciation and amortization | 16,050 | 17,581 | 47,746 | 48,564 |
| Interest expense | 33,855 | 7,792 | 100,387 | 23,240 |
| Interest income | (562) | (58) | (1,068) | (320) |
| Income taxes | 24,871 | 1,963 | 36,250 | 3,249 |
| **EBITDA from continuing operations** | 274,406 | 20,125 | 807,317 | 31,969 |
| Adjustments: |  |  |  |  |
| Pension and OPEB plan (gain) expenses(1) | 483 | 768 | 1,478 | 2,293 |
| Rationalization‑related (gains)/charges (2) | — | 1,772 | — | 994 |
| Initial public offering ("IPO") expenses (3) | 43 | — | 5,164 | — |
| Non‑cash loss (gain) on foreign currency remeasurement(4) | 1,404 | (463) | 1,629 | 3,399 |
| Stock-based compensation | 476 | — | 657 | — |
| Non‑cash fixed asset write-off | — | — | 1,062 | — |
| Related party Tax Receivable Agreement expense (5) | — | — | 61,801 | — |
| **Adjusted EBITDA from continuing operations** | 276,812 | 22,202 | 879,108 | 38,655 |

33

(1) Service and interest cost of our pension and OPEB plans. Also includes a mark‑to‑market loss (gain) for plan assets as of December of each year.

(2) Costs associated with rationalizations in our graphite electrode manufacturing operations and in the corporate structure. They include severance charges, contract termination charges, write‑off of equipment and (gain)/loss on sale of manufacturing sites.

(3) Legal, accounting, printing and registration fees associated with the initial public offering

(4) Non‑cash (gain) loss from foreign currency remeasurement of non‑operating liabilities of our non‑U.S. subsidiaries where the functional currency is the U.S. dollar.

(5) Tax-related expense for future payment to our sole pre-IPO stockholder for tax assets that are expected to be utilized.

### Key Operating Metrics

Key operating metrics consist of sales volume, weighted average realized price, production volume, production capacity and capacity utilization.

Sales volume reflects the total volume of graphite electrodes sold for which revenue has been recognized during the period. For a discussion of our revenue recognition policy, see Note 3 to the Financial Statements "Revenue from Contracts with Customers". Under our policy, volume discounts and rebates are recorded as a reduction of revenue in conjunction with the sale of the graphite electrodes. Weighted average realized price reflects the total revenues from sales of graphite electrodes for the period divided by the graphite electrode sales volume for that period. Sales volume and price help investors understand the factors that drive our net sales.

Production volume reflects graphite electrodes produced during the period. Production capacity reflects expected maximum production volume during the period under normal operating conditions, standard product mix and expected maintenance downtime. Capacity utilization reflects production volume as a percentage of production capacity. Production volume, production capacity and capacity utilization help us understand the efficiency of our production, evaluate cost of sales and consider how to approach our contract initiative.

### Results of Operations and Segment Review

### The Three Months Ended September 30, 2018 Compared to the Three Months Ended September 30, 2017

The tables presented in our period-over-period comparisons summarize our Condensed Consolidated Statements of Operations and illustrate key financial indicators used to assess the consolidated financial results. Throughout our Management Discussion and Anlaysis ("MD&A"), insignificant changes may be deemed not meaningful and are generally excluded from the discussion.

*(Dollars in thousands)*

|  | For the Three Months Ended September 30, 2018 | 2017 | Increase/ Decrease | % Change |
| --- | ---: | ---: | ---: | ---: |
| Net sales | $454,890 | $137,245 | $317,645 | 231% |
| Cost of sales | 180,280 | 120,483 | 59,797 | 50% |
| Gross profit | 274,610 | 16,762 | 257,848 | 1,538% |
| Research and development | 518 | 1,329 | (811) | (61)% |
| Selling and administrative expenses | 14,234 | 13,293 | 941 | 7% |
| Operating income | 259,858 | 2,140 | 257,718 | 12,043% |
| Other expense (income), net | 1,502 | (404) | 1,906 | (472)% |
| Interest expense | 33,855 | 7,792 | 26,063 | 334% |
| Interest income | (562) | (58) | (504) | 869% |
| Income (loss) from continuing operations before provision for income taxes | 225,063 | (5,190) | 230,253 | 4,436% |
| Provision for income taxes | 24,871 | 1,963 | 22,908 | 1,167% |
| Net income (loss) from continuing operations | 200,192 | (7,153) | 207,345 | (2,899)% |
| (Loss) income from discontinued operations, net of tax | (726) | 3,234 | (3,960) | (122)% |
| Net income (loss) | $199,466 | $(3,919) | $203,385 | 5,190% |

*Net sales.* Net sales increased from $137.2 million in the three months ended September 30, 2017 to $454.9 million in the three months ended September 30, 2018. The increase was primarily driven by a 236% increase in the weighted average sales price of graphite electrodes. The weighted average realized price increased to $9,744 per MT in the three months ended September 30, 2018 compared to $2,903 per MT in the same period of the prior year. This increase in weighted average realized price was driven by increased demand for graphite electrodes due to growth in EAF steel manufacturing, combined with a constrained graphite electrode supply due to reductions in graphite electrode manufacturing capacity over the past several years and a limited supply of our key raw material, petroleum needle coke.

We have successfully implemented our strategy to enter into take-or-pay sales agreements with our customers that range from three to five years in duration. For the three months ended September 30, 2018, approximately 79% of our revenues were generated from these contracts, with the remainder generated from other graphite electrode sales and by-product sales.

*Cost of sales.* We experienced increases in cost of sales from $120.5 million in the three months ended September 30, 2017 to $180.3 million in the three months ended September 30, 2018. This increase was primarily the result of sales of inventory that was manufactured using higher priced needle coke and pitch.

*Other expense (income).* Other expense increased from $0.4 million of income in the three months ended September 30, 2017 to $1.5 million of expense in the three months ended September 30, 2018 primarily due to disadvantageous non‑cash foreign currency impacts on non‑operating assets and liabilities.

*Interest Expense*. Interest expense increased from $7.8 million in the three months ended September 30, 2017, to $33.9 million in the three months ended September 30, 2018 primarily due to additional borrowings resulting from the February 2018 Credit Agreement and June 2018 First Amendment to the 2018 Credit Agreement.

*Provision for income taxes.* The following table summarizes the expense for income taxes:

*(Dollars in thousands)*

|  | For the Three Months Ended September 30, 2018 | 2017 |
| --- | ---: | ---: |
| Tax expense | $24,871 | $1,963 |
| Pretax income (loss) | 225,063 | (5,190) |
| Effective tax rates | 11.1% | (37.8)% |

The effective tax rate for the three months ended September 30, 2017 was (37.8)%. This rate differs from the 2017 U.S. statutory rate of 35% primarily due to losses in the U.S. and Switzerland where we received no tax benefit due to a full valuation allowance and worldwide earnings from various countries taxed at different rates. The recognition of the valuation allowance does not result in or limit the Company's ability to utilize these tax assets in the future.

The effective tax rate for the three months ended September 30, 2018 was 11.1%. This rate differs from the 2018 U.S. statutory rate of 21% primarily due to the partial release of a valuation allowance recorded against the deferred tax asset related to U.S. tax attributes and the tax impact of worldwide earnings from various countries taxed at different rates. The recognition of the valuation allowance does not result in or limit the Company's ability to utilize these tax assets in the future.

The tax expense increased from $2.0 million for the three months ended September 30, 2017 to $24.9 million for the three months ended September 30, 2018. This change is primarily due to a shift in the jurisdictional mix of earnings and losses from year to year, partially offset by the release of a portion of our valuation allowance recorded against the deferred tax assets related to U.S. tax attributes. Certain jurisdictions shifted from pre-tax losses in the three months ended September 30, 2017 to pretax earnings in the same period of 2018.

*Income from Discontinued Operations*. Our income from discontinued operations decreased from a profit of $3.2 million for the three months ended September 30, 2017 to a loss of $0.7 million in the three months ended September 30, 2018. The decrease was primarily due to the non-recurrence of a gain upon divestiture of the Advanced Graphite Materials business that was recorded in the third quarter of 2017.

### The Nine Months Ended September 30, 2018 Compared to the Nine Months Ended September 30, 2017

The tables presented in our period-over-period comparisons summarize our Condensed Consolidated Statements of Operations and illustrate key financial indicators used to assess the consolidated financial results. Throughout our MD&A, insignificant changes may be deemed not meaningful and are generally excluded from the discussion.

*(Dollars in thousands)*

|  | For the Nine Months Ended September 30, 2018 | 2017 | Increase/ Decrease | % Change |
| --- | ---: | ---: | ---: | ---: |
| Net sales | $1,363,121 | $358,298 | $1,004,823 | 280% |
| Cost of sales | 491,339 | 330,370 | 160,969 | 49% |
| Gross profit | 871,782 | 27,928 | 843,854 | 3,022% |
| Research and development | 1,528 | 3,083 | (1,555) | (50)% |
| Selling and administrative expenses | 46,349 | 37,118 | 9,231 | 25% |
| Operating income (loss) | 823,905 | (12,273) | 836,178 | 6,813% |
| Other expense (income), net | 2,533 | 4,322 | (1,789) | (41)% |
| Related party Tax Receivable Agreement expense | 61,801 | — | 61,801 | N/A |
| Interest expense | 100,387 | 23,240 | 77,147 | 332% |
| Interest income | (1,068) | (320) | (748) | 234% |
| Income (loss) from continuing operations before provision for income taxes | 660,252 | (39,515) | 699,767 | 1,771% |
| Provision for income taxes | 36,250 | 3,249 | 33,001 | 1,016% |
| Net income (loss) from continuing operations | 624,002 | (42,764) | 666,766 | 1,559% |
| Income (loss) from discontinued operations, net of tax | 585 | (4,882) | 5,467 | 112% |
| Net income (loss) | $624,587 | $(47,646) | $672,233 | 1,411% |

*Net sales.* Net sales increased by $1,004.8 million, or 280%, from $358.3 million in the nine months ended September 30, 2017 to $1,363.1 million in the nine months ended September 30, 2018. This increase was driven by a 290% increase in the weighted average realized price for graphite electrodes and a 3% increase in sales volume in the nine months ended September 30, 2018 compared to the same period in 2017. The weighted average realized price increased to $9,932 per MT in the nine months ended September 30, 2018 compared to $2,547 per MT in the same period of the prior year. These increases in weighted average realized price and sales volume were driven by increased demand for graphite electrodes due to growth in EAF steel manufacturing, combined with a constrained graphite electrode supply due to reductions in graphite electrode manufacturing capacity over the past several years and a limited supply of our key raw material, petroleum needle coke.

We have successfully implemented our strategy to enter into take-or-pay sales agreements with our customers that range from three to five years in duration. For the nine months ended September 30, 2018, approximately 72% of our revenues were generated from these contracts, with the remainder generated from other graphite electrode sales and by-product sales .

*Cost of sales.* Cost of sales increased by $161.0 million, or 49%, from $330.4 million in the nine months ended September 30, 2017 to $491.3 million in the nine months ended September 30, 2018. This increase was primarily the result of the higher input costs of needle coke and pitch.

*Selling and administrative expenses.* Selling and administrative expenses increased by $9.2 million, or 25%, from $37.1 million in the nine months ended September 30, 2017 to $46.3 million in the nine months ended September 30, 2018. This increase was driven primarily by $5.2 million of additional costs related to our IPO, a $1.7 million increase in incentive compensation expense and $0.5 million of stock based compensation expense.

*Other expense (income).* Other expense decreased by $1.8 million, or 41%, from $4.3 million in the nine months ended September 30, 2017 to $2.5 million in the nine months ended September 30, 2018. This decrease was primarily due to advantageous non‑cash foreign currency impacts on non‑operating assets and liabilities.

*Related party Tax Receivable Agreement expense.* This $61.8 million of expense is the result of our tax receivable agreement liability recorded after it was estimated in the second quarter of 2018 that we would realize certain deferred tax assets.

*Interest expense.* Interest expense increased by $77.1 million, or 332%, from $23.2 million in the nine months ended September 30, 2017 to $100.4 million in the nine months ended September 30, 2018, due to increased interest expense primarily from additional borrowings and the early extinguishment of our Senior Notes in the first quarter of 2018. These early extinguishment charges included accelerated accretion of the fair value adjustment on the Senior Notes of $18.7 million and a premium redemption of $4.8 million.

*Provision for income taxes.* The following table summarizes the expense for income taxes:

*(Dollars in thousands)*

|  | For the Nine Months Ended September 30, 2018 | 2017 |
| --- | ---: | ---: |
| Tax expense | $36,250 | $3,249 |
| Pretax income (loss) | 660,252 | (39,515) |
| Effective tax rates | 5.5% | (8.2)% |

For the nine months ended September 30, 2017, the effective tax rate of (8.2)% differs from the 2017 U.S. statutory rate of 35% primarily due to recent losses in the U.S. and Switzerland where we receive no tax benefit due to a full valuation allowance and worldwide earnings from various countries tax a different rates. The recognition of the valuation allowance does not result in or limit the Company's ability to utilize these tax assets in the future.

For the nine months ended September 30, 2018, the effective tax rate of 5.5% differs from the 2018 U.S. statutory rate of 21% primarily due the partial release of a valuation allowance recorded against the deferred tax asset related to U.S. tax attributes and worldwide earnings from various countries taxed at different rates. The recognition of the valuation allowance does not result in or limit the Company's ability to utilize these tax assets in the future.

The tax expense increased from $3.2 million for the nine months ended September 30, 2017 to $36.3 million for the nine months ended September 30, 2018. This change is primarily due to a shift in the jurisdictional mix of earnings and losses from year to year, partially offset by the release of a portion of our valuation allowance recorded against the deferred tax asset related to U.S. tax attributes. Certain jurisdictions shifted from pre-tax losses in the nine months ended September 30, 2017 to pre-tax earnings in the nine months ended September 30, 2018.

*Income (loss) from discontinued operations.* Income (loss) from our discontinued operations increased by $5.5 million, or 112%, from a loss of $4.9 million in the nine months ended September 30, 2017 to income of $0.6 million in the nine months ended September 30, 2018. This improvement was the result of the elimination of operations in 2017 and the wind-down of remaining assets into 2018.

### Effects of Changes in Currency Exchange Rates

When the currencies of non-U.S. countries in which we have a manufacturing facility decline (or increase) in value relative to the U.S. dollar, this has the effect of reducing (or increasing) the U.S. dollar equivalent cost of sales and other expenses with respect to those facilities. In certain countries in which we have manufacturing facilities, and in certain export markets, we sell in currencies other than the U.S. dollar. Accordingly, when these currencies increase (or decline) in value relative to the U.S. dollar, this has the effect of increasing (or reducing) net sales. The result of these effects is to increase (or decrease) operating profit and net income.

Many of the non-U.S. countries in which we have a manufacturing facility have been subject to significant economic and political changes, which have significantly impacted currency exchange rates. We cannot predict changes in currency exchange rates in the future or whether those changes will have net positive or negative impacts on our net sales, cost of sales or net income.

The impact of these changes in the average exchange rates of other currencies against the U.S. dollar on our net sales was a decrease of $1.1 million and an increase of $11.6 million for the three and nine months ended September 30, 2018, respectively, compared to the same periods of 2017. The impact of these changes on our cost of sales was a decrease of $2.9 million and increase of $7.6 million for the three and nine months ended September 30, 2018, respectively, compared to the same periods of 2017.

We have in the past and may in the future use various financial instruments to manage certain exposures to risks caused by currency exchange rate changes, as described under “Part I, Item 3–Quantitative and Qualitative Disclosures about Market Risk”.

### Liquidity and Capital Resources

Our sources of funds have consisted principally of cash flow from operations and debt, including our credit facilities (subject to continued compliance with the financial covenants and representations). Our uses of those funds (other than for operations) have consisted principally of dividends, capital expenditures, debt reduction payments, share repurchases and other obligations. Disruptions in the U.S. and international financial markets could adversely affect our liquidity and the cost and availability of financing to us in the future.

We believe that we have adequate liquidity to meet our needs. As of September 30, 2018, we had liquidity of $346.0 million consisting of $243.5 million of availability on our 2018 Revolving Facility (subject to continued compliance with the financial covenants and representations) and cash and cash equivalents of $102.5 million. We had long‑term debt of $2,077.0 million and short‑term debt of $106.3 million as of September 30, 2018. As of December 31, 2017, we had liquidity of $165.2 million consisting of $151.8 million available on our Old Revolving Facility (subject to continued compliance with the financial covenants and representations and adjusting for the $25 million minimum liquidity requirement) and cash and cash equivalents of $13.4 million. We had long‑term debt of $322.9 million and short‑term debt of $16.5 million as of December 31, 2017.

As of September 30, 2018 and December 31, 2017, $94.9 million and $12.6 million, respectively, of our cash and cash equivalents were located outside of the United States. We repatriate funds from our foreign subsidiaries through dividends. All of our subsidiaries face the customary statutory limitation that distributed dividends do not exceed the amount of retained and current earnings. In addition, for our subsidiary in South Africa, the South Africa Central Bank imposes that certain solvency and liquidity ratios remain above defined levels after the dividend distribution, which historically has not materially affected our ability to repatriate cash from this jurisdiction. The cash and cash equivalents balances in South Africa were $1.9 million and $1.8 million as of September 30, 2018 and December 31, 2017, respectively. Upon repatriation to the United States, the foreign source portion of dividends we receive from our foreign subsidiaries is no longer subject to U.S. federal income tax as a result of the Tax Act.

***Cash flow and plans to manage liquidity.*** Our cash flow typically fluctuates significantly between quarters due to various factors. These factors include customer order patterns, fluctuations in working capital requirements, timing of capital expenditures, acquisitions, divestitures and other factors. We had positive cash flow from operating activities during 2018, 2017 and 2016. Although the global economic environment experienced significant swings in these periods, our working capital management and cost‑control initiatives allowed us to remain operating cash‑flow positive in both times of declining and improving operating results. Cash from operations is expected to remain at positive sustained levels due to the predictable earnings generated by our three-to-five-year sales contracts with our customers.

As of September 30, 2018, we had access to the $250 million 2018 Revolving Facility. We had $6.5 million of letters of credit, for a total availability on the 2018 Revolving Facility of $243.5 million. As of December 31, 2017, we had $39.5 million of borrowings and $8.7 million of letters of credit, for a total of $48.2 million drawn against the Old Revolving Credit Facility. We also had $0.5 million of surety bonds outstanding as of both September 30, 2018 and December 31, 2017.

On February 12, 2018, we entered into the 2018 Credit Agreement, which provides for the 2018 Revolving Facility and the 2018 Term Loan Facility. On February 12, 2018, our wholly owned subsidiary, Finance, borrowed $1,500 million under the 2018 Term Loan Facility. The funds received were used to pay off our outstanding debt, including borrowings under our Old Credit Agreement and the Senior Notes and accrued interest relating to those borrowings and the Senior Notes, declare and pay a dividend of $1,112.0 million to our sole pre-IPO stockholder, pay fees and expenses incurred in connection therewith and for other general corporate purposes.

On April 19, 2018, we declared a dividend in the form of the Brookfield Promissory Note to the sole pre-IPO stockholder. The $750 million Brookfield Promissory Note was conditioned upon (i) the Senior Secured First Lien Net Leverage Ratio (as defined in the 2018 Credit Agreement), as calculated based on our final financial results for the first quarter of 2018, being equal to or less than 1.75 to 1.00, (ii) no Default or Event of Default (each as defined in the 2018 Credit Agreement) having occurred and continuing or that would result from the $750 million Brookfield Promissory Note and (iii) the satisfaction of the conditions described in (i) and (ii) above occurring within 60 days from the dividend record date. Upon publication of our first quarter report on Form 10-Q, these conditions were met and, as a result, the Brookfield Promissory Note became payable.

The Brookfield Promissory Note had a maturity of eight years from the date of issuance and bore interest at a rate equal to the Adjusted LIBO Rate (as defined in the Brookfield Promissory Note) plus an applicable margin equal to 4.50% per annum, with an additional 2.00% per annum starting from the third anniversary from the date of issuance. We were permitted to make voluntary prepayments at any time without premium or penalty. All obligations under the Brookfield Promissory Note were unsecured and guaranteed by all of our existing and future domestic wholly owned subsidiaries that guarantee, or are borrowers under, the Senior Secured Credit Facilities. No funds were lent or otherwise contributed to us by Brookfield in connection with the Brookfield Promissory Note. As a result, we received no consideration in connection with its issuance. As described below, the Brookfield Promissory Note was repaid, in full, on June 15, 2018.

On April 19, 2018, we declared a $160 million cash dividend payable to Brookfield, the sole pre-IPO stockholder. Payment of this dividend was conditional upon (i) the Senior Secured First Lien Net Leverage Ratio (as defined in the 2018 Credit Agreement), as calculated based on our final financial results for the first quarter of 2018, being equal to or less than 1.75 to 1.00, (ii) no Default or Event of Default (as defined in the 2018 Credit Agreement) having occurred and continuing or that would result from the payment of the dividend and (iii) the payment occurring within 60 days from the dividend record date. The conditions of this dividend were met upon filing of our first quarter report on Form 10-Q and the dividend was paid on May 8, 2018.

On June 15, 2018, GrafTech entered into the First Amendment to its 2018 Credit Agreement. The First Amendment amends the 2018 Credit Agreement to provide for the additional $750 million in aggregate principal amount of the Incremental Term Loans to Finance. The Incremental Term Loans increase the aggregate principal amount of term loans incurred by Finance under the 2018 Credit Agreement from $1,500 million to $2,250 million. The Incremental Term Loans have the same terms as those applicable to the existing term loans under the 2018 Credit Agreement, including interest rate, payment and prepayment terms, representations and warranties and covenants. The Incremental Term Loans mature on February 12, 2025, the same date as the existing term loans. GrafTech paid an upfront fee of 1.00% of the aggregate principal amount of the Incremental Term Loans on the effective date of the First Amendment. The proceeds of the Incremental Term Loans were used to repay, in full, the $750 million in principal outstanding on the Brookfield Promissory Note.

On August 13, 2018, the Company repurchased 11,688,311 shares directly from Brookfield. These shares were retired upon repurchase. The price per share paid by the Company was equal to the price at which the underwriters purchased the shares from Brookfield in Brookfield’s August 2018 public secondary offering of 23,000,000 shares of our common stock, net of underwriting commissions and discounts. GrafTech funded the share repurchase from cash on hand.

We currently pay a quarterly cash dividend of $0.085 per share, or an aggregate of $0.34 per share on an annualized basis. For the quarterly period ending June 30, 2018, we paid a prorated cash dividend for the period beginning on the closing date of the IPO and ending on the last day of that period. On September 28, 2018, we paid our regular quarterly dividend of $.085 per share. On November 1, 2018, the Board of Directors declared a dividend of $0.085 per share to stockholders of record as of the close of business on November 30, 2018, to be paid on December 31, 2018.

We cannot assure you, however, that we will pay dividends in the future in these amounts or at all. Our Board of Directors may change the timing and amount of any future dividend payments or eliminate the payment of future dividends in its sole discretion, without any prior notice to our stockholders. Our ability to pay dividends will depend upon many factors, including our financial position and liquidity, results of operations, legal requirements, restrictions that may be imposed by the terms of our current and future credit facilities and other debt obligations and other factors deemed relevant by our Board of Directors.

Potential uses of our liquidity include dividends, share repurchases, capital expenditures, acquisitions, debt repayments and other general purposes. Continued volatility in the global economy may require additional borrowings under the 2018 Revolving Facility. An improving economy, while resulting in improved results of operations, could increase our cash requirements to purchase inventories, make capital expenditures and fund payables and other obligations until increased accounts receivable are converted into cash. A downturn could significantly and negatively impact our results of operations and cash flows, which, coupled with increased borrowings, could negatively impact our credit ratings, our ability to comply with debt covenants, our ability to secure additional financing and the cost of such financing, if available.

In the event that operating cash flows fail to provide sufficient liquidity to meet our business needs, including capital expenditures, any such shortfall would need to be made up by increased borrowings under our 2018 Revolving Facility, to the extent available.

In order to seek to minimize our credit risks, we may reduce our sales of, or refuse to sell (except for cash on delivery or under letters of credit or parent guarantees), our products to some customers and potential customers. Our unrecovered trade receivables worldwide have not been material during the last two years individually or in the aggregate.

We manage our capital expenditures by taking into account quality, plant reliability, safety, environmental and regulatory requirements, prudent or essential maintenance requirements, global economic conditions, available capital resources, liquidity, long‑term business strategy and return on invested capital for the relevant expenditures, cost of capital and return on invested capital of the Company as a whole and other factors. We expect to have maintenance capital expenditures of approximately $35 million in 2018. Our debottlenecking initiative is expected to result in approximately $42 million of capital expenditures, slightly higher than previous estimates due mainly to currency impacts. The majority of costs associated with this initiative will be expended in 2018. We expect our debottlenecking initiative along with our maintenance capital expenditures to result in approximately $70 million of total capital expenditures in 2018.

***Related Party Transactions***. We have engaged in transactions with affiliates or related parties during the nine months ended September 30, 2018. These transactions include payment of dividends to Brookfield and entrance into and repayment of the Brookfield Promissory Note, and entrance into the Tax Receivable Agreement, Stockholders Rights Agreement, Registration Rights Agreement and Share Repurchase Agreement, each with Brookfield. On August 13, 2018, in conjunction with a follow-on offering, we purchased 11,688,311 shares directly from Brookield at a price of $19.25 per share for a total of $225 million. Additionally, during 2016, Brookfield purchased on the open market in aggregate approximately $53 million of the Senior Notes. We redeemed our Senior Notes on February 12, 2018.

We have also reimbursed certain costs incurred by Brookfield as required under the Investment Agreement dated May 4, 2015 between Brookfield and GrafTech, including in connection with, transactions with our current or former subsidiaries, compensatory transactions with directors and officers including employee benefits (including reimbursement to Brookfield for compensation costs incurred by it for certain personnel who devote substantially all of their working time to us), stock option and restricted stock grants, compensation deferral, stock purchases, and customary indemnification and expense advancement arrangements.

One of our independent directors purchased an aggregate of 5,000 shares of common stock in April 2018 in our IPO.

### Cash Flows.

The following table summarizes our cash flow activities:

*in millions*

| Cash flow provided by (used in): | For the Nine Months Ended September 30, 2018 | For the Nine Months Ended September 30, 2017 |
| --- | ---: | ---: |
| Operating activities | $612.2 | $33.6 |
| Investing activities | $(46.8) | $7.8 |
| Financing activities | $(474.7) | $(36.9) |

#### Operating Activities

Cash flow from operating activities represents cash receipts and cash disbursements related to all of our activities other than investing and financing activities. Operating cash flow is derived by adjusting net income (loss) for:

- Non-cash items such as depreciation and amortization, impairment, post retirement obligations, and severance and pension plan changes;
- Gains and losses attributed to investing and financing activities such as gains and losses on the sale of assets and unrealized currency transaction gains and losses; and
- Changes in operating assets and liabilities which reflect timing differences between the receipt and payment of cash associated with transactions and when they are recognized in results of operations.

The net impact of the changes in working capital (operating assets and liabilities), which are discussed in more detail below, include the impact of changes in: receivables, inventories, prepaid expenses, accounts payable, accrued liabilities, accrued taxes, interest payable, and payments of other current liabilities.

During the nine months ended September 30, 2018, changes in working capital resulted in a net use of funds of $143.7 million which was impacted by:

- net cash outflows in accounts receivable of $96.0 million from the increase in accounts receivable due to increased sales driven by higher weighted average realized prices, partially offset by improved collections;
- net cash outflows from increases in inventory of $93.8 million, due primarily to higher priced raw materials;
- net cash inflows from increases in accounts payable of $4.3 million, due primarily to higher priced raw materials;
- net cash inflows from decreased prepaid expense of $7.8 million due to the reduction of advanced payments; and
- net cash inflows from increased income taxes payable of $35.4 million resulting from increased profitability.

Other uses of cash in the nine months ended September 30, 2018 included contributions to pension and other benefit plans of $6.6 million, cash paid for interest of $74.5 million and taxes paid of $19.4 million.

During the nine months ended September 30, 2017, changes in working capital resulted in a net source of funds of $22.2 million which was impacted by:

- net cash inflows in accounts receivable of $2.0 million from the decrease in accounts receivable due to the collection of customer sales;
- net cash inflows from decreases in inventory of $8.6 million, due primarily to inventory management initiatives;
- net cash outflows from increased prepaid expense of $0.2 million due to advanced payments;
- net cash inflows due to increase in accounts payable and accruals of $7.1 million primarily resulting from timing of payments.

Other uses of cash in the nine months ended September 30, 2017 included contributions to pension and other benefit plans of $6.7 million, cash paid for interest of $14.6 million and taxes paid of $2.9 million.

#### Investing Activities

Net cash used investing activities was $46.8 million during the nine months ended September 30, 2018, resulting from capital expenditures of $47.6 million partially offset by proceeds from the sale of fixed assets of $0.9 million.

Net cash provided by investing activities was $7.8 million during the nine months ended September 30, 2017 resulting from proceeds from divestitures and fixed asset sales totaling $30.8 million, partially offset by capital expenditures of $23.0 million.

#### Financing Activities

Net cash outflow from financing activities was $474.7 million during the nine months ended September 30, 2018, which was the net impact of our February 12, 2018 refinancing and subsequent amendment, proceeds of which were used to repay outstanding debt, pay dividends of $1,316.2 million, and repay the $750 million Brookfield Promissory Note to Brookfield. We also repurchased $225 million of our common stock from Brookfield on August 13, 2018.

Net cash outflow from financing activities was $36.9 million during the nine months ended September 30, 2017, resulting from net payments on our Revolving Facility.

***Long-Term Contractual, Commercial and Other Obligations and Commitments.*** The following table updates our long-term contractual obligations and other commercial commitments as of December 31, 2017 to reflect, on a pro forma basis: (A)(i) our entrance into the 2018 Credit Agreement and the borrowing of $1,500 million of 2018 Term Loans thereunder in February 2018; and (ii) the use of proceeds therefrom to, among other things, repay in full all outstanding indebtedness under the Old Credit Agreement and redeem in full the Senior Notes at a redemption price of 101.594% of the principal amount thereof plus accrued and unpaid interest to the date of redemption; (B) the issuance of the Brookfield Promissory Note in May 2018; (C)(i) our entrance into the First Amendment to the 2018 Credit Agreement and the borrowing of the $750 million of Incremental Term Loans thereunder in June 2018; and (ii) the repayment in full of the $750 million in principal amount outstanding on the Brookfield Promissory Note; and (D) additional purchase obligations for 2018, primarily for raw materials, that were entered into since the filing of our year-end financial statements.

*(in thousands)*

| Contractual and Other Obligations | Pro Forma Contractual Obligations Total | 2018 | 2019-2020 | 2021-2022 | 2023+ |
| --- | ---: | ---: | ---: | ---: | ---: |
| 2018 Term Loan Facility (a) | $2,250,000 | $56,250 | $225,000 | $225,000 | $1,743,750 |
| Pro Forma Interest on Long-term Debt (a) | $819,130 | $105,140 | $258,226 | $235,281 | $220,483 |
| Leases | 6,188 | 2,180 | 2,646 | 713 | 649 |
| Total contractual obligations | 3,075,318 | 163,570 | 485,872 | 460,994 | 1,964,882 |
| Postretirement, pension and related benefits (b) | 115,557 | 11,717 | 22,986 | 22,853 | 58,001 |
| Committed purchase obligations (c) | 140,785 | 140,785 | — | — | — |
| Other long-term obligations | 8,463 | 6,721 | 723 | 392 | 627 |
| Uncertain income tax provisions | 2,492 | 379 | 1,990 | 123 | — |
| Total contractual and other obligations (d) | $3,342,615 | $323,172 | $511,571 | $484,362 | $2,023,510 |
| **Other Commercial Commitments** |  |  |  |  |  |
| Guarantees (e) | 525 | 525 | — | — | — |
| Total other commercial commitments | $525 | $525 | $— | $— | $— |

(a) On February 12, 2018, the Company entered into the 2018 Credit Agreement, which provided for the 2018 Term Loan Facility and 2018 Revolving Credit Facility. On February 12, 2018, Finance borrowed $1,500 million of 2018 Term Loans under the 2018 Term Loan Facility. The proceeds of the 2018 Term Loans were used, among other things, to pay off our outstanding debt, including borrowings under the Old Credit Agreement and the Senior Notes and related interest. On April 19, 2018, the Company declared a dividend in the form of the $750 million Brookfield Promissory Note to the sole pre-IPO stockholder. On June 15, 2018, the Company entered into the First Amendment to the 2018 Credit Agreement, which provided for an additional $750 million in aggregate principal amount of Incremental Term Loans. The Company borrowed $750 million in Incremental Term Loans on June 15, 2018. The proceeds of the Incremental Term Loans were used to repay the Brookfield Promissory Note in full. The 2018 Term Loans and the Incremental Term Loans mature on February 12, 2025 and bear interest at a rate equal to either the Adjusted LIBO Rate, plus an applicable margin initially equal to 3.50% per annum, or the ABR Rate, plus an applicable margin initially equal to 2.50% per annum, in each case with one step down of 25 basis points based on achievement of certain public ratings of the 2018 Term Loans, as applicable (see "Liquidity and Capital Resources" for details). The pro forma interest on indebtedness under the 2018 Credit Agreement was estimated using a monthly LIBOR yield curve through February 2025.

(b) Represents estimated postretirement, pension and related benefits obligations based on actuarial calculations.

(c) Represents commitments made for purchases related to our ongoing plant expansion projects and committed purchases of raw materials. Includes committed purchases of raw materials for the second half of 2018 for which pricing was established in June and July 2018.

(d) In addition, letters of credit of $8.7 million were issued under the Old Revolving Facility as of December 31, 2017. These letters of credit were rolled over to the 2018 Revolving Facility in February 2018.

(e) Represents surety bonds which are renewed annually. If rates were unfavorable, we would use letters of credit under our revolving facility.

### Recent Accounting Pronouncements

We discuss recently adopted accounting standards in Note 1, “Organization and Summary of Significant Accounting Policies” of the Notes to Condensed Consolidated Financial Statements.

### Description of Our Financing Structure

We discuss our financing structure in more detail in Note 6, “Debt and Liquidity” of the Notes to Condensed Consolidated Financial Statements.

## Market risk

As filed, 4,742 characters.

We are exposed to market risks primarily from changes in interest rates, currency exchange rates, energy commodity prices and commercial energy rates. We, from time to time, routinely enter into various transactions that have been authorized according to documented policies and procedures to manage these well-defined risks. These transactions relate primarily to financial instruments described below. Since the counterparties to these financial instruments are large commercial banks and similar financial institutions, we do not believe that we are exposed to material counterparty credit risk. We do not use financial instruments for trading purposes.

Our exposure to changes in interest rates results primarily from floating rate long-term debt tied to LIBOR or Euro LIBOR. Our exposure to changes in currency exchange rates results primarily from:

- sales made by our subsidiaries in currencies other than local currencies;
- raw material purchases made by our foreign subsidiaries in currencies other than local currencies; and
- investments in and intercompany loans to our foreign subsidiaries and our share of the earnings of those subsidiaries, to the extent denominated in currencies other than the dollar.

Our exposure to changes in energy commodity prices and commercial energy rates results primarily from the purchase or sale of refined oil products and the purchase of natural gas and electricity for use in our manufacturing operations.

***Currency Rate Management.*** We enter into foreign currency derivatives from time to time to attempt to manage exposure to changes in currency exchange rates. These foreign currency derivatives, which include, but are not limited to, forward exchange contracts and purchased currency options, attempt to hedge global currency exposures. Forward exchange contracts are agreements to exchange different currencies at a specified future date and at a specified rate. Purchased foreign currency options are instruments which give the holder the right, but not the obligation, to exchange different currencies at a specified rate at a specified date or over a range of specified dates. Forward exchange contracts and purchased currency options are carried at market value.

The outstanding foreign currency derivatives represented no net unrealized gain or loss as of September 30, 2018 and a net unrealized loss as of $0.1 million as of December 31, 2017.

***Energy Commodity Management***. We have entered into commodity derivative contracts to effectively fix some or all of our exposure to refined oil products. The outstanding commodity derivative contracts represented a net unrealized gain of $40.9 million as of September 30, 2018 and a net unrealized gain of $4.7 million as of December 31, 2017.

***Interest Rate Risk Management.*** We periodically implement interest rate management initiatives to seek to minimize our interest expense and the risk in our portfolio of fixed and variable interest rate obligations.

We periodically enter into agreements with financial institutions that are intended to limit, or cap, our exposure to incurrence of additional interest expense due to increases in variable interest rates. These instruments effectively cap our interest rate exposure. We currently do not have any such instruments outstanding.

***Sensitivity Analysis.*** We use sensitivity analysis to quantify potential impacts that market rate changes may have on the fair values of our foreign currency derivatives and our commodity derivatives. The sensitivity analysis represents the hypothetical changes in value of the hedge position and does not reflect the related gain or loss on the forecasted underlying transaction. As of September 30, 2018, a 10% appreciation or depreciation in the value of the U.S. dollar against foreign currencies from the prevailing market rates would result in a corresponding decrease of $1.0 million or a corresponding increase of $1.0 million, respectively, in the fair value of the foreign currency hedge portfolio. A 10% increase or decrease in the value of the underlying commodity prices that we hedge would result in a corresponding increase or decrease of $15.5 million in the fair value of the commodity hedge portfolio as of September 30, 2018. Because of the high correlation between the hedging instrument and the underlying exposure, fluctuations in the value of the instruments are generally offset by reciprocal changes in the value of the underlying exposure.

We had no interest rate derivative instruments outstanding as of September 30, 2018. A hypothetical increase in interest rates of 100 basis points (1%) would have increased our interest expense by $12.6 million for the nine months ended September 30, 2018.

## Controls and procedures

As filed, 1,663 characters.

*Evaluation of Disclosure Controls and Procedures.* Management is responsible for establishing and maintaining adequate disclosure controls and procedures at the reasonable assurance level. Disclosure controls and procedures are designed to ensure that information required to be disclosed by a reporting company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by it in the reports that it files under the Exchange Act is accumulated and communicated to management, including the Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure.

Under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, we have evaluated the effectiveness of the design and operation of our disclosure controls and procedures as of September 30, 2018. Based on that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that these controls and procedures are effective at the reasonable assurance level as of September 30, 2018.

*Changes in Internal Control over Financial Reporting*. There have been no changes in our internal control over financial reporting that occurred during the three months ended September 30, 2018 that materially affected or are reasonably likely to materially affect our internal control over financial reporting.

## Risk factors

As filed, 192 characters.

There have been no material changes to the Risk Factors disclosed in Part II - Item 1A of our first quarter report on Form10-Q filed on May 7, 2018, which are incorporated herein by reference.

Filed Nov 2, 2018.
Source: SEC EDGAR, the filing index for accession 0000931148-18-000034. Last ingested by Listed: Nov 10, 2026, 00:15 ET. No prices; not investment advice.
